ArticleJournal of translational medicine2015
Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.
Article in Journal of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- A Microfluidic-Based Sensing Platform for Rapid Quality Control on Target Cells from Bioreactors.Sensors (Basel, Switzerland) · 2024Article
- Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy.Cancer immunology research · 2023Article
- Emerging CAR T Cell Strategies for the Treatment of AML.Cancers · 2022Review
- The antigen-binding moiety in the driver's seat of CARs.Medicinal research reviews · 2022Review
- CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia.Cell reports · 2021Article
- Genetic engineering of T cells for immunotherapy.Nature reviews. Genetics · 2021Review
- CAR-T cells: Early successes in blood cancer and challenges in solid tumors.Acta pharmaceutica Sinica. B · 2021Review
- Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin's Lymphoma Cells.Frontiers in cell and developmental biology · 2021Article
- Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.Journal of genetics and genomics = Yi chuan xue bao · 2020Review
- Promoter choice: Who should drive the CAR in T cells?PloS one · 2020Article
- Inducible Gene Switches with Memory in Human T Cells for Cellular Immunotherapy.ACS synthetic biology · 2019Article
- Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Influence of various medium environment to in vitro human T cell culture.In vitro cellular & developmental biology. Animal · 2018Article
- Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression.Nature communications · 2018Article
- CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.Trends in molecular medicine · 2017Review
- Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy.Journal of the National Cancer Institute · 2016Review
- T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.Cancer immunology research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundT cells expressing chimeric antigen receptors (CARs) have shown exciting promise in cancer therapy, particularly in the treatment of B-cell malignancies. However, optimization of CAR-T cell production remains a trial-and-error exercise due to a lack of phenotypic benchmarks that are clearly predictive of anti-tumor functionality. A close examination of the dynamic changes experienced by CAR-T cells upon stimulation can improve understanding of CAR-T-cell biology and identify potential points for optimization in the production of highly functional T cells.
methodsPrimary human T cells expressing a second-generation, anti-CD19 CAR were systematically examined for changes in phenotypic and functional responses to antigen exposure over time. Multi-color flow cytometry was performed to quantify dynamic changes in CAR-T cell viability, proliferation, as well as expression of various activation and exhaustion markers in response to varied antigen stimulation conditions.
resultsStimulated CAR-T cells consistently bifurcate into two distinct subpopulations, only one of which (CAR(hi)/CD25(+)) exhibit anti-tumor functions. The use of central memory T cells as the starting population and the resilience-but not antigen density-of antigen-presenting cells used to expand CAR-T cells were identified as critical parameters that augment the production of functionally superior T cells. We further demonstrate that the CAR(hi)/CD25(+) subpopulation upregulates PD-1 but is resistant to PD-L1-induced dysfunction.
conclusionsCAR-T cells expanded ex vivo for adoptive T-cell therapy undergo dynamic phenotypic changes during the expansion process and result in two distinct populations with dramatically different functional capacities. Significant and sustained CD25 and CAR expression upregulation is predictive of robust anti-tumor functionality in antigen-stimulated T cells, despite their correlation with persistent PD-1 upregulation. The functionally superior subpopulation can be selectively augmented by careful calibration of antigen stimulation and the enrichment of central memory T-cell type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.